Explore Our Biomarker Menu

Biomarker:

TNF-RII (plasma)

Biological or Clinical Significance:

Tumor Necrosis Factor Receptor Type II is an inhibitor of TNF and can block TNF bioactivity. Recombinant human TNF-RII produced in CHO is a dimeric, glycosylated, polypeptide chain consisting of the extraCellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of TNFRII contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. Potency is determined by its ability to neutralize TNF-α mediated growth inhibition of A375 cells, corresponding to a Specific Activity of 1.7 x 10⁷ IU/mg.

References:

Analyte:

TNF-RII (plasma)

Matrix:

Human PPP Plasma

Status:

Experienced Running

Sensitivity-LLOQ:

5.00 pg/mL

Sensitivity-ULOQ:

9,000 pg/mL

platform

MSD-ECL

Required Sample Volume

25 µL/well

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.